SACHS BRUCE I 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Nov 8, 2023
Insider Transaction Report
Form 4
SACHS BRUCE I
Director
Transactions
- Sale
Common Stock
2023-11-06$385.00/sh−11,250$4,331,250→ 40,000 total - Exercise/Conversion
Common Stock
2023-11-06$127.54/sh+11,250$1,434,825→ 51,250 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-06−11,250→ 11,250 totalExercise: $127.54Exp: 2025-05-31→ Common Stock (11,250 underlying)
Footnotes (4)
- [F1]Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.
- [F2]Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $385.00 (range $385.00 to $385.02).
- [F4]Fully vested.